NMTC Stock Forecast: NeuroOne Medical Technologies Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores NeuroOne Medical Technologies Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (58): The business earns solid, repeatable profits on what it owns.
Momentum (4): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NMTC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NMTC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Maxim Group | Maintains | Buy | $13 → $5.00 |
| 13 May 2026 | Ladenburg Thalmann | Maintains | Buy | $1.60 → $8.00 |
| 2 Mar 2026 | Jones Trading | Initiates | Buy | — |
| 9 Sept 2025 | Maxim Group | Initiates | Buy | — |
| 5 May 2025 | Ladenburg Thalmann | Initiates | Buy | — |
| 15 Aug 2023 | Alliance Global Partners | Maintains | Buy | — |
| 28 Mar 2022 | Craig-Hallum | Downgrade | Hold | — |
| 3 Dec 2021 | Alliance Global Partners | Initiates | Buy | — |
| 15 Nov 2021 | Craig-Hallum | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
NMTC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NMTC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, NeuroOne Medical Technologies Corp. returned −81.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NMTC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.5×
- Price / book
- 1.6×
- EV / EBITDA
- —
Cheaper than 79% of US stocks
Cheaper than 51% of US stocks
- Revenue growth (YoY)
- 16.3%
- Earnings growth (YoY)
- —
- Gross margin
- 59.9%
- Operating margin
- −63.4%
- Net margin
- —
Higher than 65% of US stocks
Higher than 73% of US stocks
Higher than 17% of US stocks
- Return on equity
- −124.7%
- Return on assets
- −58.1%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NeuroOne Medical Technologies Corp. has a market value of $6.1M and an enterprise value of $4.3M.
Revenue in the twelve months to 30 June 2026: $9.5M. The latest quarter grew 16.3% year on year.
Net income over the same four quarters: −$7.4M, a −78.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$7.2M.
NeuroOne Medical Technologies Corp. spent $70K on share buybacks in the twelve months to 30 June 2026.
NeuroOne Medical Technologies Corp. employs 18 people — $526K of revenue per employee.
Data provided by Twelve Data
NMTC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NMTC’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own NeuroOne Medical Technologies Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NMTC
How does Ticker Nerd's model rank NMTC?
As at 21 Nov 2026, NeuroOne Medical Technologies Corp. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (58 of 100).
What is the NMTC stock forecast for 2030?
No analyst covering NeuroOne Medical Technologies Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NMTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8.8 over the next 12 months.
How has NMTC stock performed over the past year?
NeuroOne Medical Technologies Corp. returned -81.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does NeuroOne Medical Technologies Corp. do?
NeuroOne Medical Technologies Corporation is a medical technology company focused on diagnostic and therapeutic solutions for neurological disorders. The company develops and commercializes thin-film electrode technology for continuous electroencephalogram and stereoelectroencephalography recording, along with minimally invasive systems for brain ablation, stimulation, and drug delivery.
About NeuroOne Medical Technologies Corp.
NeuroOne Medical Technologies Corporation is a medical technology company focused on diagnostic and therapeutic solutions for neurological disorders. The company develops and commercializes thin-film electrode technology for continuous electroencephalogram and stereoelectroencephalography recording, along with minimally invasive systems for brain ablation, stimulation, and drug delivery. Its product portfolio includes Evo cortical electrodes, Evo sEEG electrodes, and OneRF ablation systems designed for neurosurgery, neurology, and pain management applications. NeuroOne Medical Technologies Corporation serves clinical settings that treat conditions such as epilepsy, trigeminal neuralgia, Parkinson’s disease, dystonia, essential tremor, and chronic pain. Based in Eden Prairie, Minnesota, the company plays a specialized role in the neurotechnology market by supporting more precise monitoring and treatment options for patients with complex brain and nerve-related disorders.
CEO Mr. David A. Rosa M.D. · 18 employees · United States · https://nmtc1.com